Kornimate/medical-research-clean huggingface dataset:
hyperimmune plasma for patients with covid-19

Conditions: Covid19

Summary: the outbreak of severe acute respiratory syndrome coronavirus 2 (sars-cov-2), which originated in wuhan, china, has become a major concern all over the world. convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with sars whose condition continued to deteriorate despite treatment with pulsed methylprednisolone. moreover, several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma. evidence shows that convalescent plasma from patients who have recovered from viral infections can be used effectively as a treatment of patients with active disease. to date, no specific treatment has been proven to be effective. the investigators plan to treat critical covid-19 patients with hyperimmune plasma.

apheresis from recovered donors will be performed with a cell separator device , with 500-600 ml of plasma obtained from each donor. donors are males and womens , age 18 yrs or more, evaluated for transmissible diseases according to the italian law. adjunctive tests will be for hepatitis a virus, hepatitis e virus and parvovirus b-19. all donors will be tested for the covid-19 neutralizing title. each plasma bag obtained from plasmapheresis will be immediately divided in two units and frozen according to the national standards and stored separately. based on experience published in literature 250-300 ml of convalescent plasma will be used to treat each of the recruited patients at most 3 times over 5 days.

Eligibility criteria:
inclusion criteria: * age \>=18 yrs * positive for reverse transcription polymerase chain reaction (rt-pcr) severe acute respiratory syndrome (sars)-cov-2 * acute respiratory distress syndrome (ards) moderate to severe, according to berlin definition, lasting less than10 days * polymerase chain reaction (pcr) positive * signed informed consent unless unfeasible for the critical condition exclusion criteria: * proven hypersensitivity or allergic reaction to hemoderivatives or immunoglobulins * consent denied

Keywords: covid19 hospitalized patients hyperimmune plasma
physical status and upper airway function in neuromuscular patients

Conditions: Neuromuscular Diseases; Physical Disability; Airway Disease

Summary: inside of studies that report an upper airway function impaired, the upper limb strength has been demonstrated to be determinant in breath, speech and swallow performance. nevertheless, no previous studies in neuromuscular disease have explored the relation between general disability and upper airway function. there is a suspicion of upper airway which is associated with physical deterioration, however the extent to which if feeds back has not been explored.


Eligibility criteria:
inclusion criteria: * diagnosis of neuromuscular disease * between 6 and 65 years * impairment of the upper airway * accepted to sign the informed consent exclusion criteria: * cognitive impairment. * diagnose of autism spectrum disorder or severe intellectual disability * physical or functional impairment that limits the performance of evaluation
research of prognostic factors associated with healing of venous leg ulcers

Conditions: Leg Ulcer

Summary: this study was undertaken to identify prospectively which clinical venous leg ulcer (vlu) characteristics known as possible prognostic markers, and which sociodemographic and psychologic factors associated with vlu are associated with complete healing at 24 weeks.


Eligibility criteria:
inclusion criteria: * ambulatory or hospitalized patients * patients over 50 years old * one or more venous leg ulcer, lasting for 1 month or more * wound area more than 1 cm2 * clinical findings consistent with established venous disease (skin hyperpigmentation, varicose veins, lipodermatosclerosis), confirmed by venous doppler duplex ultrasonography performed during the preceding 6 months * absence of significant arterial insufficiency assessed by clinical findings (intermittent claudication or resting pain, necrotic or distal foot wound) and by an ankle brachial index (abi) ≥0.8 * ability to give informed consent * ability to be followed for 24 weeks exclusion criteria: * ongoing systemic diseases known to be associated with pyoderma gangrenosum or necrotizing vasculitis * corticosteroid, cytotoxic or immunosuppressant drug use during the preceding 3 months * hypertensive leg ulcer * foot ulcer * abi \< 0.8

Keywords: venous leg ulcer healing prognostic factors
triceps taping on elbow flexion tightness in extended erb's palsy

Conditions: Deformity Flexion

Summary: to determine the role of using kinesiology tape on the prevention of elbow flexion tightness in infants with extended erb's palsy.

purpose: to determine the role of using kinesiology tape on the prevention of elbow flexion tightness in infants with extended erb's palsy. background: background neglecting or even delay in brachial plexus birth palsy management, may result in substantial and chronic impairment. physiotherapy, microsurgical nerve reconstruction, secondary joint corrections, and muscle transpositions are employed to help the child maximize function in the affected upper extremity. kinesiology taping can have an effect on muscle performance and support joint by improving proprioception, normalizing muscle tone, correct the inappropriate positions and stimulate skin receptors. the possible effect of kinesiotaping on muscle strength has been investigated by numerous researchers that have theorized that kinesiotaping facilitates an immediate increase in muscle strength by generating a concentric pull on the fascia. hypotheses: there will be no role of kinesiology tape on the prevention of elbow flexion tightness in infants with extended erb's palsy. research question: is there a role of using kinesiology tape in preventing elbow flexion tightness in infants with extended erb's palsy?

Eligibility criteria:
inclusion criteria: * 3-6 months of age * had unilateral extended bpbp involving cervical 5, 6, and 7 roots lesion * based on an emg referral by a physiatrist * had positive grasp reflex on both sides * had asymmetrical moro reflex on the affected side. exclusion criteria: - surgical interferences arm fracture or dislocations hypersensitivity to latex and adhesive tapes
experimental techniques for early identification of autism

Conditions: Autism Spectrum Disorder; Infant Development

Summary: this project deals with essential challenges in the context of autism spectrum disorder, benefiting from a longitudinal design in infancy and a cutting-edge electroencephalogram/eye-tracking integrated approach. the investigators will focus on multisensory audiovisual integration to identify early markers of autism in infants at-risk for autism. the investigators will characterize early derailments from the typical developmental trajectories to identify critical "time windows" and better describe the heterogeneity of autism.

autism spectrum disorder is a heterogeneous condition characterized by atypical social communication and repetitive patterns of behavior, with recent italian prevalence estimates of one in 77. the heterogeneity of autism is expressed in individual variation not only in the severity of core symptoms but also in cognitive, language, and behavioral skills, which show different developmental trajectories. moreover, there is a strong interest in identifying reliable behavioral and brain-based predictors, which may constitute useful tools for early detection of at-risk cases. in particular, autistic individuals perform poorly during conditions that require integration across multiple sensory modalities such as audiovisual sensory integration, and process differently social and non-social stimuli compared to neurotypical counterparts. however, the study of potential interaction between sensory and social processing in the first years of life is still scarce. no study examined early social and sensory markers in infant siblings of autistic children using integrated experimental techniques. the study includes siblings of autistic children and neurotypical toddlers recruited at 18 months and a follow-up evaluation is collected at 24 months. at both time-points, all children are assessed with an experimental protocol, including behavioral and neurophysiological measures. the integrated electroencephalogram -eyetracking task focuses on sensory processing in social (face saying "wow" in infant-directed speech) and non-social (spinning top toy) conditions. presented videos are presented both in synchronous and asynchronous modalities (1000 ms delay audio presentation). electroencephalographic signal is recorded by high-density 128-channel system and pupil dilations are recorded using a tobii prospectrum 300 hertz system. in addition, complete information about clinical measures is collected for all children at 18 and 24 months.

Eligibility criteria:
inclusion criteria: * infants aged between 6 and 36 months * toddlers at elevated likelihood of developing autism because siblings of children with autism exclusion criteria: * gestational age \<36 weeks * griffiths general quotient \< 70 * presence of major complications in pregnancy and/or delivery likely to affect brain development * presence of neurological deficits, dysmorphic markers, or other medical conditions

Keywords: siblings biomarker autism infants
the effect of two different modes of anaesthesia mainantance on postoperative delirium

Conditions: Cognitive Dysfunction, Cognitive Disorder; Delirium - Postoperative

Summary: in this study, the cognitive status of the patients in the preoperative period was taken into consideration and the development of delirium after the surgery was investigated. there is no harm to the patient.

the patients were preoperatively assessed for american society of anesthesiologists (asa) risk by an anesthetist and age, sex and comorbidities were recorded. the mini-cog test was applied as a cognitive screening test by the anesthesiologist in the preoperative period and the test score was recorded. three-word memory test, clock drawing, and visual function test was performed to evaluate the patient's cognitive functions. in this test, patients were asked to memorize three words such as umbrella, sunshine, and chair at the beginning of the test.

Eligibility criteria:
inclusion criteria: * there was a correlation between the incidence of delirium after the age of 60(10). exclusion criteria: * patients' age\&lt; 60 years, * patients undergoing emergency cholecystectomy or did not have preoperative mini-cog assessment, * with a history of cerebrovaskuler insult that was thought to have an effect on postoperative delirium , * patients with difficulty in cooperation , * patients with hemodynamic instability(arterial blood pressure above 160/90 mmhg and below 90/60 mmhg and patients with pulse rate below 50/min and above 100/min) , * patients with previously diagnosed dementia, and those who had surgical procedures lasting more than 2 hours were excluded from the study.

Keywords: delirium mini-cog anaesthesia
inhaled steroids at discharge after emergency department visits for children with uncontrolled asthma

Conditions: Asthma

Summary: many children have asthma and this causes problems with their health. a lot of children with uncontrolled asthma use emergency departments for asthma care, and so this is an ideal place for an intervention for these children. one intervention is prescribing inhaled steroids to children with uncontrolled asthma, but currently this is rarely done in the emergency department. inhaled steroids have been shown to be good at making children better long-term when they have uncontrolled asthma. this study identifies children in the emergency department with uncontrolled asthma using a tool called the pediatric asthma control and communication instrument (pacci). if children meet criteria for uncontrolled asthma they will be randomly assigned to either: 1) routine asthma care which includes close follow up with their doctor or 2) prescribing of an inhaled corticosteroid from the emergency department. the investigators hypothesize that children who are prescribed inhaled steroids for uncontrolled asthma from the emergency department will have better 6 month asthma control than children who receive routine asthma care.

specific aim 1 - an ed-based rct to determine if ics prescription in children identified using the pacci as having uncontrolled asthma results in less asthma morbidity compared to routine asthma care. we hypothesize that children receiving ics prescriptions will have fewer unscheduled health care use for asthma exacerbations (doctor's office visits, ed visits, or hospitalizations), and greater quality of life. specific aim 2 - thematic analysis of interviews with parents who are adherent versus non-adherent with ics prescription filling and use to determine the factors associated with adherence. we hypothesize that factors will include: 1) parent beliefs about the chronic versus episodic nature of asthma, 2) parent's knowledge of benefits and risks of ics, and 3) provision and use of an asthma action plan.

Eligibility criteria:
inclusion criteria: * 3 - 12 years of age * child has asthma diagnosed by a doctor based on parental/caregiver report * child is not already properly using an ics or being discharged with an ics exclusion criteria: * the child has previously participated in this study * the child has major co-morbid disease of the heart or lungs (examples include cystic fibrosis, heart disease, muscular dystrophy and cerebral palsy with immobility. it does not include allergic rhinitis or a history of respiratory infections such as pneumonia or bronchiolitis. * the child's parents/caregivers do not speak english * the child is not going to be discharged from the emergency department (e.g. hospitalization)

Keywords: asthma children inhaled corticosteroids emergency department
irbesartan/hydrochlorothiazide national taiwan university hospital listing

Conditions: Hypertension

Summary: primary: 1. to compare the change in forearm vascular resistance following a 12-week regimen of irbesartan/hydrochlorothiazide versus irbesartan 2. to assess changes of serum proinflammatory cytokine, markers of cardiovascular risks, oxidative stress and circulating adhesion molecule including thiobarbiturate acid reactive substances (tbars), c-reactive protein (crp), interleukin 6 (il-6), and vascular cell adhesion molecule 1 (vcam-1). secondary: 1. to compare the reduction in office blood pressure following a 12-week regimen of irbesartan/hydrochlorothiazide versus irbesartan 2. to compare the response rate (defined as office systolic blood pressure(sbp)/diastolic blood pressure (dbp) reduce more than 10mmhg from baseline), and bp controlled rate (defined as sbp\<140 mmhg and /or dbp\<90 mmhg) 3. to ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus irbesartan when administered once daily 4. to determine whether angiotensin ii type 1 (at-1) receptor gene polymorphisms (including a1166c gene with about 4% of the minor allele frequency in chinese population and other single nucleotide polymorphisms with a higher frequency of about 10% of minor allele) is related to reduction of bp


Eligibility criteria:
inclusion criteria: patients with mild to moderate hypertension with office diastolic bp (dbp) 90-109 mmhg and/or systolic bp (sbp) 140-179 mmhg before entering each treatment exclusion criteria: * females: who are pregnant or breast feeding * office dbp ≧ 110 mmhg or office sbp ≧ 180 mmhg * history of significant cardiovascular diseases which include: acute myocardial infarction within six months or any ischemic heart disease requiring medication, or cerebrovascular disease * history of significant renal diseases including: serum creatinine \> 3.0 mg/dl, or creatinine clearance \< 30 ml/min. * severe biliary cirrhosis and cholestasis * refractory hypokalemia, hypercalcemia * history of autoimmune disease, collagen vascular disease, multiple drug allergies, bronchospastic disease or other malignancies requiring current medication * hepatic disease as indicated by any of the following : serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvate transaminase (sgpt) \>3 x upper limit of normal, or serum bilirubin \> 2 x upper limit of normal the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
regression of hamstring flexibility and performance in children with duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy; Performance; Flexibility

Summary: investigator investigated that regression of hamstring flexibility and performance in children with duchenne muscular dystrophy.

flexibility of hamstrings was evaluated by popliteal angle test. performance was evaluated 6 minute walk test (6 mwt). regression of hamstring flexibility and performance was examined regression tests. correlation was examined between popliteal angle test and parameter of north star ambulation assessment.

Eligibility criteria:
inclusion criteria: * to be a duchenne muscular dystrophy diagnosis, * being in the ambulatory period and climbing four steps independently, * to be level 1 and level 2 according to brooke lower functional classification test * to be able to cooperate * no any severe contracture in the lower limbs which may prevent assessments, exclusion criteria: * children who fail to meet these criteria study.

Keywords: duchenne muscular dystrophy performance hamstring flexibility regression
canola oil multicentre intervention trial

Conditions: Metabolic Syndrome

Summary: the purpose of the study is to examine how the consumption of different dietary oil varieties affects a broad range of metabolic responses that are important in the development of cardiovascular diseases. this study will examine the relationship between dietary oil consumption and arterial function, blood fat content, and blood markers of cardiovascular disease risk. additionally, the efficiency of the body in converting fat from dietary oils into other specific fat compounds with know health benefits will be examined. also, the correlation between psychosocial parameters and vascular function will be studied.

although consumption of omega-3 fatty acids favorably modulate circulating lipids and arterial health, there is confusion surrounding the specific health benefits of plant based alpha-linolenic acid (ala) versus marine derived eicosapentaenoic acid (epa) and docosahexaenoic acid (dha). this research will examine the health benefits of ala from consumption of diets rich in canola oil, novel monounsaturated fatty acid (mufa) and dha enriched canola oils, and flax oil compared with a control diet representative of north american diets rich in omega-6 and saturated fats. treatment oils will be examined for potential influence on endothelial dysfunction, inflammation, oxidation, body composition, and plasma lipoprotein characterization. furthermore, in an effort to elucidate the genetic factors that promote ala conversion to epa/dha and strengthen the role of ala in cardiovascular health, a major objective is to correlate common genetic variants in the fatty acid desaturase 1 (fads1) and fatty acid desaturase 2 (fads2) gene cluster with ala conversion to epa/dha and n-3 fatty acid composition of serum phospholipids in response to consumption of the treatment oils. besides, psychosocial predictors of vascular function will be investigated.

Eligibility criteria:
inclusion criteria: * waist circumference ≥94 cm (males) or ≥80 cm (females) plus at least one of the following: * triglycerides ≥1.7 mmol/l * high density lipoprotein (hdl) cholesterol \<1 mmol/l (males) or \<1.3 mmol/l (females) * low density lipoprotein (ldl) cholesterol ≥3.5 mmol/l * blood pressure ≥130 mmhg (systolic) and/or ≥85 mmhg (diastolic) * glucose ≥5.5 mmol/l exclusion criteria: * thyroid disease * diabetes mellitus * kidney disease * liver disease * smoking * heavy drinking * use of medication known to affect lipid metabolism during the last 3 months(cholestyramine, colestipol, niacin, clofibrate, gemfibrozil, probucol, hmg coa reductase inhibitors)

Keywords: canola oil high oleic canola oil flax oil ala dha metabolic syndrome cardiovascular disease endothelial function fads1 gut microbiome body composition psychosocial status cholesterol lipids lipoproteins inflammation lipid peroxidation
a single dose, tolerance and pharmacokinetic study in obese or overweight type 2 diabetic volunteers

Conditions: Diabetes Mellitus; Obesity

Summary: the purpose of this study is to evaluate the safety and tolerance of a single intravenous (through a vein) dose of trodusquemine (msi-1436) in obese, type 2 diabetics. different amounts of trodusquemine (msi-1436) will be given to each volunteer group throughout the study. another purpose is to evaluate the pharmacokinetics (pk - the study of the way the drug enters and leaves the blood and tissues over time) of trodusquemine (msi-1436). finally, this study will also determine whether trodusquemine (msi-1436) has any effect on appetite, mood or behavior, and selective biomarkers (substances in your blood that may change in response to the study drug).


Eligibility criteria:
inclusion criteria: 1. male or female obese or overweight type 2 diabetic subjects, between 18 and 55 years old (inclusive) 2. either treatment naive or who are inadequately controlled on either metformin alone or metformin in combination with a sulfonylurea. subjects on metformin in combination with a sulfonylurea will be allowed a 2 week period to wash out the sulfonylurea before dosing. 3. have a fasting blood sugar of ≥ 100 mg/dl, hemoglobin a1c ≥ 7.5% (but ≤ 11.0%). subjects on a combination of metformin and sulfonylurea must have a hemoglobin a1c ≥ 7.5% (but ≤ 10.0%); 4. non-smoker 5. body mass index (bmi) of 27-40 kg/m2 exclusion criteria: 1. likely allergy or sensitivity to any components of trodusquemine (msi-1436) for injection based on known allergies to drugs of the same class; 2. any subject with a history of allergy (rash, hives, breathing difficulty, etc.) to any medications, either prescription or nonprescription, including dietary supplements or herbal medications; 3. any subject with a history of severe allergy or bronchial asthma; 4. a clinically significant history of or current abnormality or disease of any organ system, including renal, hepatic, gastrointestinal, cardiovascular (except hyperlipidemia or controlled hypertension), pulmonary (including chronic asthma), endocrine (except diabetes), central nervous, or hematologic systems, or recent clinically significant surgery;